Transcriptional Control of Glioma Stem Cells by a Novel LGALS1/HOXA5 Signalling Pathway

新型 LGALS1/HOXA5 信号通路对神经胶质瘤干细胞的转录控制

• 批准号: 461900
• 负责人: Jahani-Asl Arezu
• 金额: $ 61.02万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-03-01 至 2027-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=461900&lang=en
• 关键词: Hoxa5; Lgals1; Patient-Derived Stem Cells; Scrna-Seq; Self-Renewal; Transcription

Glioblastoma (GB) is the most malignant primary brain tumor in adults. The present standard of care includes maximal surgical removal of the tumors followed by treatment with Temozolomide (TMZ) and ionizing radiation (IR). Despite these intense efforts, t

胶质母细胞瘤（GB）是成人中最恶性的原发性脑肿瘤。目前的护理标准包括最大程度地手术切除肿瘤，然后用替莫唑胺 (TMZ) 和电离辐射 (IR) 治疗。尽管做出了这些巨大的努力，